Plus Therapeutics Inc (PSTV) Stock
PSTV is no longer traded. Plus Therapeutics was delisted from the Nasdaq in August 2026.
Prices on this page are historical; the last trade was August 7, 2026 at $3.84.
Plus Therapeutics stock price history
PSTV final trading statistics
- Final close
- $3.84
- Final trading day
- Aug 7, 2026
- Market cap at delisting
- $26.42M
- Shares outstanding
- 6.88M
- Final 52-week range
- $0.13 – $8.00
- Avg. volume (final 3 mo.)
- 159,319
- All-time high (split-adj.)
- $1000000.00 · Jul 2001
- All-time low (split-adj.)
- $2.92 · Apr 2026
- Return since IPO
- -100.0%
- Beta
- 1.42
- Book value / share
- $1.74
- Price / book
- 2.20
Plus Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $5.21M | -$22.4M | -$15.37 |
| FY2024 | $5.82M | -$13.0M | -$39.74 |
| FY2023 | $4.91M | -$13.3M | -$93.09 |
| FY2022 | $224.0K | -$20.3M | -$232.72 |
| FY2021 | $0.00 | -$13.4M | -$322.54 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Plus Therapeutics stock FAQ
What happened to Plus Therapeutics stock?
Plus Therapeutics stock was delisted from the Nasdaq. Its final close was $3.84 on August 7, 2026.
Is PSTV stock still trading?
No. PSTV was delisted from the Nasdaq in August 2026 and no longer trades on a U.S. exchange.
What was the last price of PSTV stock?
PSTV closed at $3.84 on its final trading day, August 7, 2026, for a market value of about $26.42M.
What were Plus Therapeutics's revenue and earnings in its last full fiscal year?
Plus Therapeutics reported revenue of $5.21M and net income of -$22.4M in fiscal 2025, its last full year as a public company.
When did Plus Therapeutics go public?
Plus Therapeutics Inc stock began trading on November 16, 2000.